Professor Henry Kitchener MD FRCOG FRCS(Glas) FMedSci

Photograph of Henry Kitchener

Chair of Gynaecological Oncology

Academic O&G
Research - 5th Floor
St Mary's Hospital
Oxford Road
M13 9WL


Henry Kitchener's research group is engaged in a portfolio which includes basic science aimed at HPV target discovery; HPV vaccine trials both prophylactic and therapeutic; a randomised trial of HPV testing in cervical screening involving 25,000 women; a randomised trial of automated reading of cervical cytology. This involves molecular and cell biology and multidisciplinary clinical trial teams both inside and outside Manchester. Funders include MRC, Heath Technology Assessment Programme, CRUK as well as national and local charities.


Henry Kitchener graduated in 1975. Between 1980-82 he was Florence and William Blair-Bell Research Fellow in the MRC Virology Unit in Glasgow. During this time he investigated the presence of viral genome in cervical cancer, graduating MD in 1983. He then worked as Clinical Lecturer in the University of Singapore and became Consultant/Senior Lecturer at University of Aberdeen in 1988.

In 1996 he moved to a new Chair of Gynaecological Oncology in the University of Manchester. Over the Past 20 years the focus of this work has been Human Papillomavirus including its role in cervical carcinogenesis; its role as a cervical screening test and translational studies of HPV vaccines in vulval intraepithelial neoplasia. Since 1997 he has served on the DH Advisory Committee on Cervical Screening and since 2003 has been Chair of the NCRI Gynaecological Studies Group.  In 2003 he was invited to be Visiting Professor in Oncology at McGill University, Montreal.  In 2007 he was elected to the Fellowship of the Academy of Medical Sciences.



  • Albrow, R., Blomberg, K., Kitchener, H., Brabin, L., Patnick, J., Tishelman, C., Törnberg, S., Sparén, P. & Widmark, C (2014). Interventions to improve cervical cancer screening uptake amongst young women: a systematic review. Acta Oncol, 53(4), 445-51. eScholarID:240271 | PMID:24660768 | DOI:10.3109/0284186X.2013.869618
  • Alemany, L., Saunier, M., Tinoco, L., Quirós, B., Alvarado-Cabrero, I., Alejo, M., Joura, E., Maldonado, P., Klaustermeier, J., Salmerón, J., Bergeron, C., Petry, K., Guimerà, N., Clavero, O., Murillo, R., Clavel, C., Wain, V., Geraets, D., Jach, R., Cross, P., Carrilho, C., Molina, C., Shin, H., Mandys, V., Nowakowski, A., Vidal, A., Lombardi, L., Kitchener, H., Sica, A., Magaña-León, C., Pawlita, M., Quint, W., Bravo, I., Muñoz, N., de Sanjosé, S., Bosch, F. & . (2014). Large contribution of human papillomavirus in vaginal neoplastic lesions: A worldwide study in 597 samples. Eur J Cancer, 50(16), 2846-54. eScholarID:240266 | PMID:25155250 | DOI:10.1016/j.ejca.2014.07.018
  • Castellsagué, X., Naud, P., Chow, S., Wheeler, C., Germar, M., Lehtinen, M., Paavonen, J., Jaisamrarn, U., Garland, S., Salmerón, J., Apter, D., Kitchener, H., Teixeira, J., Skinner, S., Limson, G., Szarewski, A., Romanowski, B., Aoki, F., Schwarz, T., Poppe, W., Bosch, F., de Carvalho, N., Peters, K., Tjalma, W., Safaeian, M., Raillard, A., Descamps, D., Struyf, F., Dubin, G., Rosillon, D. & Baril, L (2014). Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. J Infect Dis, 210(4), 517-34. eScholarID:240269 | PMID:24610876 | DOI:10.1093/infdis/jiu139
  • Cherry, N., McNamee, R., Heagerty, A., Kitchener, H. & Hannaford, P (2014). Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial. BJOG, 121(6), 700-5; discussion 705. eScholarID:240264 | PMID:24533510 | DOI:10.1111/1471-0528.12598
  • Cuschieri, K., Cubie, H., Graham, C., Rowan, J., Hardie, A., Horne, A., Earle, C., Bailey, A., Crosbie, E. & Kitchener, H (2014). Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age. J Clin Virol, 59(2), 104-8. eScholarID:240263 | PMID:24380720 | DOI:10.1016/j.jcv.2013.12.001
  • Flatley, J., Sargent, A., Kitchener, H., Russell, J. & Powers, H (2014). Tumour suppressor gene methylation and cervical cell folate concentration are determinants of high-risk human papillomavirus persistence: a nested case control study. BMC Cancer, 14, 803. eScholarID:240270 | PMID:25367268 | DOI:10.1186/1471-2407-14-803
  • Jayson, G., Kohn, E., Kitchener, H. & Ledermann, J (2014). Ovarian cancer. Lancet, 384(9951), 1376-88. eScholarID:240265 | PMID:24767708 | DOI:10.1016/S0140-6736(13)62146-7
  • Moss, S., Bailey, A., Cubie, H., Denton, K., Sargent, A., Muir, P., Vipond, I., Winder, R. & Kitchener, H (2014). Comparison of the performance of HPV tests in women with abnormal cytology: results of a study within the NHS cervical screening programme. Cytopathology, eScholarID:240262 | PMID:25274541 | DOI:10.1111/cyt.12210
  • Ronco, G., Dillner, J., Elfström, K., Tunesi, S., Snijders, P., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., Berkhof, J., Peto, J., Meijer, C. & . (2014). Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet, 383(9916), 524-32. eScholarID:240260 | PMID:24192252 | DOI:10.1016/S0140-6736(13)62218-7
  • Skinner, S., Szarewski, A., Romanowski, B., Garland, S., Lazcano-Ponce, E., Salmerón, J., Del Rosario-Raymundo, M., Verheijen, R., Quek, S., da Silva, D., Kitchener, H., Fong, K., Bouchard, C., Money, D., Ilancheran, A., Cruickshank, M., Levin, M., Chatterjee, A., Stapleton, J., Martens, M., Quint, W., David, M., Meric, D., Hardt, K., Descamps, D., Geeraerts, B., Struyf, F., Dubin, G. & . (2014). Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet, eScholarID:240267 | PMID:25189358 | DOI:10.1016/S0140-6736(14)60920-X
  • Wang, J., Jagu, S., Wang, C., Kitchener, H., Daayana, S., Stern, P., Pang, S., Day, P., Huh, W. & Roden, R (2014). Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions. PLoS One, 9(7), e101576. eScholarID:240268 | PMID:24999962 | DOI:10.1371/journal.pone.0101576


  • Bowring, J., Albrow, R., Fisher, A., Downey, G., Cullimore, J., Patnick, J., Walker, P. & Kitchener, H (2013). A prospective study of human papillomavirus (HPV) testing to resolve uncertainty in colposcopy. Cytopathology, 24(5), 309-13. eScholarID:240258 | PMID:22925374 | DOI:10.1111/j.1365-2303.2012.01003.x
  • Crosbie, E., Einstein, M., Franceschi, S. & Kitchener, H (2013). Human papillomavirus and cervical cancer. Lancet, eScholarID:197294 | PMID:23618600 | DOI:10.1016/S0140-6736(13)60022-7
  • Kitchener, H., Denton, K., Soldan, K. & Crosbie, E (2013). Developing role of HPV in cervical cancer prevention. BMJ, 347, f4781. eScholarID:240261 | PMID:23926316
  • Sadler, L., Albrow, R., Shelton, R., Kitchener, H. & Brabin, L (2013). Development of a pre-notification leaflet to encourage uptake of cervical screening at first invitation: a qualitative study. Health Educ Res, 28(5), 793-802. eScholarID:240259 | PMID:23111151 | DOI:10.1093/her/cys103
  • Tidy, J., Brown, B., Healey, T., Daayana, S., Martin, M., Prendiville, W. & Kitchener, H (2013). Accuracy of detection of high-grade cervical intraepithelial neoplasia using electrical impedance spectroscopy with colposcopy. BJOG, 120(4), 400-10; discussion 410-1. eScholarID:197280 | PMID:23289897 | DOI:10.1111/1471-0528.12096


  • Albrow, R., Kitchener, H., Gupta, N. & Desai, M (2012). Cervical screening in England: the past, present, and future. Cancer Cytopathol, 120(2), 87-96. eScholarID:197285 | PMID:22367883 | DOI:10.1002/cncy.20203
  • Bowring, J., Albrow, R., Fisher, A., Downey, G., Cullimore, J., Patnick, J., Walker, P. & Kitchener, H (2012). A prospective study of human papillomavirus (HPV) testing to resolve uncertainty in colposcopy. Cytopathology, eScholarID:197281 | PMID:22925374 | DOI:10.1111/j.1365-2303.2012.01003.x
  • Crosbie, E. & Kitchener, H (2012). Human papillomavirus as a target for management, prevention and therapy. Int J Hyperthermia, 28(6), 478-88. eScholarID:197289 | PMID:22690976 | DOI:10.3109/02656736.2012.677934
  • Crosbie, E., Roberts, C., Qian, W., Swart, A., Kitchener, H. & Renehan, A (2012). Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial. Eur J Cancer, 48(6), 853-64. eScholarID:197284 | PMID:22100903 | DOI:10.1016/j.ejca.2011.10.003
  • Kelly, R., Walker, P., Kitchener, H. & Moss, S (2012). Incidence of cervical intraepithelial neoplasia grade 2 or worse in colposcopy-negative/human papillomavirus-positive women with low-grade cytological abnormalities. BJOG, 119(1), 20-5. eScholarID:197300 | PMID:21624034 | DOI:10.1111/j.1471-0528.2011.02970.x
  • Kitchener, H. & Paraskevaidis, E (2012). Patient's preference: a sound basis for policy? BJOG, 119(1), 5-6. eScholarID:197290 | PMID:22168605 | DOI:10.1111/j.1471-0528.2011.03157.x
  • Kong, A., Johnson, N., Kitchener, H. & Lawrie, T (2012). Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev, 3, CD003916. eScholarID:197283 | PMID:22419290 | DOI:10.1002/14651858.CD003916.pub3
  • Kong, A., Johnson, N., Kitchener, H. & Lawrie, T (2012). Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst, 104(21), 1625-34. eScholarID:197282 | PMID:22962693 | DOI:10.1093/jnci/djs374
  • Legood, R., Sadique, Z., Patnick, J., Kitchener, H., Kelly, R. & Moss, S (2012). Cost and logistics of alternative roll-out options for implementing human papillomavirus testing as a triage in cervical screening: results of the sentinel sites study. Br J Cancer, 107(9), 1574-9. eScholarID:197287 | PMID:23037717 | DOI:10.1038/bjc.2012.435
  • Legood, R., Smith, M., Lew, J., Walker, R., Moss, S., Kitchener, H., Patnick, J. & Canfell, K (2012). Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study. BMJ, 345, e7086. eScholarID:197286 | PMID:23117060
  • Lehtinen M, Paavonen J, Wheeler CM, Kitchener et al. (2012). Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cercial intraepithelial neoplasia: 4-year end-fo-study analysis of the randomised double-blind PATRICIA trial. Lancet Oncology, 13(1), 89-99. eScholarID:144731 | DOI:10.1016/S1470-2045(11)70286-8
  • Lehtinen, M., Paavonen, J., Wheeler, C., Jaisamrarn, U., Garland, S., Castellsagué, X., Skinner, S., Apter, D., Naud, P., Salmerón, J., Chow, S., Kitchener, H., Teixeira, J., Hedrick, J., Limson, G., Szarewski, A., Romanowski, B., Aoki, F., Schwarz, T., Poppe, W., De Carvalho, N., Germar, M., Peters, K., Mindel, A., De Sutter, P., Bosch, F., David, M., Descamps, D., Struyf, F., Dubin, G. & . (2012). Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol, 13(1), 89-99. eScholarID:197293 | PMID:22075171 | DOI:10.1016/S1470-2045(11)70286-8
  • Roset Bahmanyar, E., Paavonen, J., Naud, P., Salmerón, J., Chow, S., Apter, D., Kitchener, H., Castellsagué, X., Teixeira, J., Skinner, S., Jaisamrarn, U., Limson, G., Garland, S., Szarewski, A., Romanowski, B., Aoki, F., Schwarz, T., Poppe, W., De Carvalho, N., Harper, D., Bosch, F., Raillard, A., Descamps, D., Struyf, F., Lehtinen, M., Dubin, G. & . (2012). Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol, 127(3), 440-50. eScholarID:197291 | PMID:22940493 | DOI:10.1016/j.ygyno.2012.08.033
  • Sadler, L., Albrow, R., Shelton, R., Kitchener, H. & Brabin, L (2012). Development of a pre-notification leaflet to encourage uptake of cervical screening at first invitation: a qualitative study. Health Educ Res, eScholarID:197296 | PMID:23111151 | DOI:10.1093/her/cys103
  • Stern, P., van der Burg, S., Hampson, I., Broker, T., Fiander, A., Lacey, C., Kitchener, H. & Einstein, M (2012). Therapy of human papillomavirus-related disease. Vaccine, 30 Suppl 5, F71-82. eScholarID:197295 | PMID:23199967 | DOI:10.1016/j.vaccine.2012.05.091
  • Szarewski, A., Poppe, W., Skinner, S., Wheeler, C., Paavonen, J., Naud, P., Salmeron, J., Chow, S., Apter, D., Kitchener, H., Castellsagué, X., Teixeira, J., Hedrick, J., Jaisamrarn, U., Limson, G., Garland, S., Romanowski, B., Aoki, F., Schwarz, T., Bosch, F., Harper, D., Hardt, K., Zahaf, T., Descamps, D., Struyf, F., Lehtinen, M., Dubin, G. & . (2012). Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer, 131(1), 106-16. eScholarID:197299 | PMID:21858807 | DOI:10.1002/ijc.26362
  • Teschendorff, A., Jones, A., Fiegl, H., Sargent, A., Zhuang, J., Kitchener, H. & Widschwendter, M (2012). Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Med, 4(3), 24. eScholarID:197297 | PMID:22453031 | DOI:10.1186/gm323
  • Wheeler CM, Castellsague X, Garland SM, Kitchener HC et al. (2012). Cross-protective efficacy of HPV-16/18 AS adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types. Lancet Oncology, 13(1), 100-110. eScholarID:144750 | DOI:10.1016/S1470-2045(11)70287-X
  • Wheeler, C., Castellsagué, X., Garland, S., Szarewski, A., Paavonen, J., Naud, P., Salmerón, J., Chow, S., Apter, D., Kitchener, H., Teixeira, J., Skinner, S., Jaisamrarn, U., Limson, G., Romanowski, B., Aoki, F., Schwarz, T., Poppe, W., Bosch, F., Harper, D., Huh, W., Hardt, K., Zahaf, T., Descamps, D., Struyf, F., Dubin, G., Lehtinen, M. & . (2012). Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol, 13(1), 100-10. eScholarID:197288 | PMID:22075170 | DOI:10.1016/S1470-2045(11)70287-X
  • Winter-Roach, B., Kitchener, H. & Lawrie, T (2012). Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev, 3, CD004706. eScholarID:197279 | PMID:22419298 | DOI:10.1002/14651858.CD004706.pub4
  • Zhuang, J., Jones, A., Lee, S., Ng, E., Fiegl, H., Zikan, M., Cibula, D., Sargent, A., Salvesen, H., Jacobs, I., Kitchener, H., Teschendorff, A. & Widschwendter, M (2012). The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. PLoS Genet, 8(2), e1002517. eScholarID:197292 | PMID:22346766 | DOI:10.1371/journal.pgen.1002517


  • Almonte M, Silva Idos S, Asare A, Kitchener HC et al. (2011). Sexual behaviour and HPV infection in British women, by postal questionnaire and telephone interviews. Journal of Medical Virology, 83(7), 1238-1246. eScholarID:144784 | DOI:10.1002/jmv.22085
  • Bacon M, Kitchener HC, Stuart GC, VErmorken JB et al. (2011). The global impace of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer. Inernational Journal of Cancer, 21(4), 746-749. eScholarID:144782
  • Crosbie EJ, Roberts C, Qian W, Swart AM, Kitchener HC, Renehan AG. (In-press). Body mass index does not influence post-treatment survival in early stage endometrial cancer. European Journal of Cancer, eScholarID:144723
  • Daayna S, Winters U, Stern PL, Kitchener HC. (2011). Clinical and immunological response to photodynamic therapy i the treatment of vulval intraepithelial neoplasia. Photochemical and Photobiological Science, 10(5), 802-809. eScholarID:144786 | DOI:10.1039/c0pp00344a
  • Foley G, Alson R, Geraci M, Brabin L, Kitchener H, Birch J. (2011). Increasing rates of cervical cancer in young women in England: An analysis of national data 1982-2006. British Journal of Cancer, 105(1), 177-184. eScholarID:144670 | DOI:10.1038/bjc.2011.196
  • Friedlander M, Trimble E, Tinker A, Kitchener HC et al. (2011). Clinical trials in recurrent ovarian cancer. International Journal of Cancer, 21(4), 771-775. eScholarID:144778 | DOI:10.1097/IGC.0b013e31821bb8aa
  • Kelly RS, Patnick J, Kitchener HC, Moss SM. (2011). HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: Results from the Sentinel Sites Study. British Journal of Cancer, 105(7), 983-988. eScholarID:144720 | DOI:10.1038/bjc.2011.326
  • Kitchener HC, Blanks R, Dunn G, Gunn L, Desai M, Albrow R, Mather J, Rana DN, Cubie H, Moore C, Legood R, Gray A, Moss S. (2011). Automation-assisted versus manual reading of cervical cytology (MAVARIC): a randomised controlled trial. Lancet Oncology, 12(1), 56-64. eScholarID:105707 | DOI:10.1016/S1470-2045(10)70264-3
  • Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, Desai M, Mather J, Turner A, Moss S, Peto J. (2011). A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: Extented follow-up on the ARTISTIC trial. European Journal of Cancer, 47, 864-871. eScholarID:144669 | DOI:10.1016/j.ejca.2011.01.008
  • Kitchener HC. (2011). Sentinel-node biopsy in endometrial cancer: A win-win scenario? Lancet Oncology, 12(5), 413-414. eScholarID:144788 | DOI:10.1016/S1470-2045(11)70093-6
  • Ledermann JA, Marth C, Carey MS, Kitchener HC et al. (2011). Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. International Journal of Cancer, 21(4), 763-770. eScholarID:144776 | DOI:10.1097/IGC.0b013e31821b2669
  • Lyratazopoulos G, Newsom H, Barbiere J, Bolton D, Wright K, Kitchener H, Greenberg D. (2011). Trends in the surgical management of epithelial ovarian cancer in East Anglia 1995-2006. European Journal of Surgical Oncology, 37(5), 435-441. eScholarID:144667 | DOI:10.1016/j.ejso.2011.02.004
  • Martin-Hirsch, P., Bryant, A., Keep, S., Kitchener, H. & Lilford, R (2011). Adjuvant progestagens for endometrial cancer. Cochrane Database Syst Rev, (6), CD001040. eScholarID:197298 | PMID:21678331 | DOI:10.1002/14651858.CD001040.pub2
  • Stuart GC, Kitchener HC, Bacon M, duBois A et al. (2011). Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: Report from the Fourth Ovarian Cancer Consensus Conference. International Journal of Cancer, 21(4), 750-755. eScholarID:144780 | DOI:10.1097/IGC.0b013e31821b2568
  • Szarewski A, Poppe WA, Skinner SR, Kitchener HC et al for the PATRICIA Study Group. (2011). Efficacy of the human papillomavirus HPV16/18 AS04 Adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV16/18. International Journal of Cancer, eScholarID:144762
  • Thigpen T, duBois A, McAlpine J, Kitchener HC et al. (2011). First-line terapy in ovarian cancer trials. International Journal of Cancer, 21(4), 756-762. eScholarID:144779 | DOI:10.1097/IGC.0b013e31821ce75d
  • Kitchener HC, Blanks R, Cubie H, Desia M, Dunn G, Legood R, Gray A, Sadique A, Moss S. (2011). MAVARIC - A comparison of automation-assisted and manual cervical screening: A randomised controlled trial. Southampton: Health Technology Assessment. eScholarID:144718


  • Cole, C., Lau, S., Backen, A., Clamp, A., Rushton, G., Dive, C., Hodgkinson, C., McVey, R., Kitchener, H. & Jayson, G (2010). Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther, 10(5), eScholarID:88539 | PMID:20595807 | DOI:10.4161/cbt.10.5.12585
  • Howell-Jones, R., Bailey, A., Beddows, S., Sargent, A., de Silva, N., Wilson, G., Anton, J., Nichols, T., Soldan, K., Kitchener, H. & . (2010). Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br J Cancer, 103(2), 209-16. eScholarID:88538 | PMID:20628396 | DOI:10.1038/sj.bjc.6605747
  • Kitchener, H., Hoskins, W., Small, W., Thomas, G., Trimble, E. & . (2010). The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report. Int J Gynecol Cancer, 20(6), 1092-100. eScholarID:88537 | PMID:20683424 | DOI:10.1111/IGC.0b013e3181e730aa
  • Power ZL, Kitchener HC, Campbell MG, Waterman HA. (2010). The Hyperemesis Impact of Symptoms Questionnaire: development and validation of a clinical tool. International Journal of Nursing Studies, 47(1), 67-77. eScholarID:1d28399 | DOI:10.1016/j.ijnurstu.2009.06.012


  • Kitchener, HC, Almonte, M, Thomson, C, Wheeler, P, Sargent, A, Stoykova, B, Gilham, C, Baysson, H, Roberts, C, Dowie, R, Desai, M, Mather, J, Bailey, A, Turner, A, Moss, S, Peto, J. (2009). HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncology, 10(7), 672-82. eScholarID:1d19929 | DOI:10.1016/S1470-2045(09)70156-1
  • Kitchener, Henry Charles, Maribel Almonte, Clare Gilham, Boyka Stoykova, Alex Sargent, Chris Roberts, Mina Desai, and Julian Peto. (2009). ARTISTIC: a randomised trial of human papillimavirus (HPV testing in primary cervical screening. Southampton: Health Technology Assessment. eScholarID:78302


  • Brabin L, Roberts SA, Farzaneh F, Fairbrother E, Kitchener HC. (2008). The second to fourth digit ratio (2D:4D) in women with and without human papillomavirus and cervical dysplasia. Am J Hum Biol, 20( 3), eScholarID:1d19669 | DOI:10.1002/ajhb.20731
  • Kitchener, HC, Walker, P, Nelson, L, Hadwin, R, Patnick, J, Anthony, G, Sargent, A, Wood, J, Moore, C, Cruickshank, M. (2008). HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia. BJOG, 115( 8), eScholarID:1d19935 | DOI:10.1111/j.1471-0528.2008.01748.x
  • Vallely L, Roberts SA, Kitchener HC, Brabin L. (2008). Informing adolescents about human papillomavirus vaccination: what will parents allow? Vaccine, 26( 18), eScholarID:1d19668 | DOI:10.1016/j.vaccine.2008.02.055


  • Brabin L, Roberts SA, Kitchener HC. (2007). A semi-qualitative study of attitudes to vaccinating adolescents against human papillomavirus without parental consent. BMC Public Health, 7, eScholarID:1d15567
  • Crosbie E, Kitchener HC. (2007). Cervarix--a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer. Expert Opin Biol Ther, 7( 3), 391-6. eScholarID:1d31285
  • Paavonen, J, Jenkins, D, Bosch, F, Naud, P, Salmerón, J, Wheeler, C, Chow, S, Kitchener, HC, Castellsague, X, de Carvalho, N, Skinner, S, Harper, D, Hedrick, J, Jaisamrarn, U, Limson, G, Dionne, M, Quint, W, Spiessens, B, Peeters, P, Struyf, F, Wieting, S, Lehtinen, M, Dubin, G, NULL. (2007). Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet, 369( 9580), 2161-70. eScholarID:1d31383 | DOI:10.1016/S0140-6736(07)60946-5
  • Rosa, D, Ton, N, Clamp, A, Mullamitha, S, Lau, S, Clayton, R, Kitchener, HC, Shanks, J, McVey, R, Jayson, G-. (2007). The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma. Clin Oncol (R Coll Radiol), 19(2), 125-128. eScholarID:1d31282 | DOI:10.1016/j.clon.2006.11.015


  • Board, RE, Bruijns, CT, Pronk, AE, Ryder, WD, Wilkinson, PM, Welch, R, Shanks, JH, Connolly, G, Slade, RRJ, Reynolds, K, Kitchener, HC, Jayson, G-. (2006). Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer centre. Int J Gynecol Cancer, 16 (Suppl 1), 18-24. eScholarID:1d15476 | DOI:10.1111/j.1525-1438.2006.00308.x
  • Davies P, Arbyn M, Dillner J, Kitchener HC, Meijer CJLM, Ronco G, Hakama M. (2006). A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. IJC, 118(4), 791-796. eScholarID:1d15466
  • Farzaneh F, Roberts SA, Mandal D, Ollier WER, Winters U, Kitchener HC, Brabin L. (2006). The IL-1082G polymorphism is associated with clearance of HPV infection. British Journal Of Obstetrics And Gynaecology, 113(8), 961-964. eScholarID:1d27020
  • Fiander AN, Tristram AJ, Davidson SE, Tomlinson AE, Man S, Baldwin PJ, Sterling JC, Kitchener HC. (2006). Prime-boost vaccination strategy in women with high-grade, non-cervical anogenital intraepithelial neoplasia: clinical results from a multicentre phase II trial. Int J Gynecol Cancer, 16, 1075-1081. eScholarID:1d15474 | DOI:10.1111/j.1525-1438.2006.00598.x
  • Hampson L, Kitchener HC, Hampson IN. (2006). Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6 dependent cervical carcinoma cells in vitro. Antiviral Therapy, 11 (6), 813-825. eScholarID:1d13089
  • Jain P, Hunter RD, Livsey JE, Coyle C, Kitchener HC, Swindell R, Davidson SE. (2006). Pattern of failure and long term morbidity on patients undergoing postoperative radiotherapy for cervical cancer. IJGC, 16(5), 1839-1845. eScholarID:1d15470
  • Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, Sargent A, Peto J. (2006). HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer, 95( 1), 56-61. eScholarID:1d31291
  • Kitchener HC, Dunn G, Lawton V, Reid F, Nelson L, Smith A. (2006). Laparoscopic versus open colposuspension--results of a prospective randomised controlled trial. BJOG, 113( 9), 1007-13. eScholarID:1d31365
  • Moss S, Gray A, Legood R, Vessey M, Patnick J, Kitchener HC. (2006). Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study. BMJ, 332 (7533), 83-85. eScholarID:1d13059 | DOI:10.1136/bmj.38701.440961.7C
  • Rosa, DD, Clamp, A, Mullamitha, S, Ton, N, Sin Lau, Byrd, L, Slade, RRJ, Clayton, R N, Kitchener, HC, Shanks, JH, Wilson, GGR, McVey, R, Hasan, I, Swindell, R, Jayson, G-. (2006). The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Eur J Surg Oncol, 32, 588-591. eScholarID:1d15185 | DOI:10.1016/j.ejso.2006.02.013


  • Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener HC. (2003). Management of women who test positive for high-risk types of human papillomavirus: the HART Study. The Lancet, 362 (9399), 1871-1876. eScholarID:1d10174 | DOI:10.1016/S0140-6736(03)14955-0
  • Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ, Dobson J, Roberts JS, Hickling J, Kitchener, HC, Stern, PL. (2003). Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res, 63(18):, 6032-41.. eScholarID:1d7521


  • Hampson L, El Hady ES, Moore JV, Kitchener HC, Hampson IN. (2001). The HPV16 E6 and E7 proteins and the radiation resistance of cervical carcinoma. Faseb Journal, 15(8), eScholarID:1d3848 | DOI:10.1096/fj.00-0728fje


  • Stern PL, Brown MD, Stacey S.N, Kitchener HC, Hampson IN, Abdel-Hady E.S, Moore JV. (2000). Natural HPV immunity and vaccination strategies. J Clin Virol, 19, eScholarID:1d3076

  • Ronco G, Dillner J, Elfstrom M, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJ. (In-press). Efficacy of HPV-based Screening for Preventing Invasive Cervical Cancer: follow-up of European randomised controlled trials. Lancet, eScholarID:210632